Neon Therapeutics

General Information


We are a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes.

Employees: 84
Founded: 2013
Contact Information
Address 40 Erie Street, Suite 110, Cambridge, MA 02139, US
Phone Number (617) 337-4701
Web Address
View Prospectus: Neon Therapeutics
Financial Information
Market Cap $451.2mil
Revenues $0 mil (last 12 months)
Net Income $-65.7 mil (last 12 months)
IPO Profile
Symbol NTGN
Exchange NASDAQ
Shares (millions): 6.3
Price range $16.00 - $16.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch/ Mizuho Securities
CO-Managers Oppenheimer
Expected To Trade: 6/27/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change